Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14th
November 07 2017 - 4:05PM
Business Wire
-- Presentation to be webcast on
www.exelixis.com --
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.
Morrissey, Ph.D., the company’s President and Chief Executive
Officer, will provide an overview of the company at Stifel’s 2017
Healthcare Conference taking place November 14-15 in New York, NY.
The Exelixis presentation is scheduled for 11:45 AM EST / 8:45 AM
PST on Tuesday, November 14, 2017.
To access the webcast link, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the presentation to ensure
adequate time for any software download that may be required to
listen to the webcast. A replay will also be available at the same
location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before
entering into partnerships with leading biopharmaceutical companies
in our efforts to bring them to patients globally. With growing
revenues from the three resulting commercialized products –
CABOMETYX®, COMETRIQ®, and COTELLIC® – we are reinvesting in our
business to maximize the potential of our pipeline, which we intend
to supplement with targeted business development activities and
internal drug discovery, all to deliver the next generation of
Exelixis medicines and help patients recover stronger and live
longer. For more information about Exelixis, please visit
www.exelixis.com or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171107006659/en/
Investors Contact:Exelixis, Inc.Susan Hubbard,
650-837-8194EVP, Public Affairs and Investor
Relationsshubbard@exelixis.comorMedia Contact:For Exelixis,
Inc.Hal Mackins, 415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2024 to May 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From May 2023 to May 2024